1
|
Narayan P, Ahsan MD, Webster EM, Perez L, Levi SR, Harvey B, Wolfe I, Beaumont S, Brewer JT, Siegel D, Thomas C, Christos P, Hickner A, Chapman-Davis E, Cantillo E, Holcomb K, Sharaf RN, Frey MK. Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol 2023; 177:72-85. [PMID: 37651980 DOI: 10.1016/j.ygyno.2023.07.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 07/24/2023] [Accepted: 07/28/2023] [Indexed: 09/02/2023]
Abstract
OBJECTIVE Approximately 20% of ovarian cancers are due to an underlying germline pathogenic variant. While pathogenic variants in several genes have been well-established in the development of hereditary ovarian cancer (e.g. BRCA1/2, RAD51C, RAD51D, BRIP1, mismatch repair genes), the role of partner and localizer of BRCA2 (PALB2) remains uncertain. We sought to utilize meta-analysis to evaluate the association between PALB2 germline pathogenic variants and ovarian cancer. METHODS We conducted a systematic review and meta-analysis. We searched key electronic databases to identify studies evaluating multigene panel testing in people with ovarian cancer. Eligible trials were subjected to meta-analysis. RESULTS Fifty-five studies met inclusion criteria, including 48,194 people with ovarian cancer and information available on germline PALB2 pathogenic variant status. Among people with ovarian cancer and available PALB2 sequencing data, 0.4% [95% CI 0.3-0.4] harbored a germline pathogenic variant in the PALB2 gene. The pooled odds ratio (OR) for carrying a PALB2 pathogenic variant among the ovarian cancer population of 20,474 individuals who underwent germline testing was 2.48 [95% CI 1.57-3.90] relative to 123,883 controls. CONCLUSIONS Our meta-analysis demonstrates that the pooled OR for harboring a PALB2 germline pathogenic variant among people with ovarian cancer compared to the general population is 2.48 [95% CI 1.57-3.90]. Prospective studies evaluating the role of germline PALB2 pathogenic variants in the development of ovarian cancer are warranted.
Collapse
|
2
|
Siraj AK, Bu R, Parvathareddy SK, Iqbal K, Azam S, Qadri Z, Al-Rasheed M, Haqawi W, Diaz M, Victoria IG, Al-Badawi IA, Tulbah A, Al-Dayel F, Ajarim D, Al-Kuraya KS. PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients. Sci Rep 2023; 13:7666. [PMID: 37169825 PMCID: PMC10175539 DOI: 10.1038/s41598-023-34693-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Accepted: 05/05/2023] [Indexed: 05/13/2023] Open
Abstract
The PALB2 gene is a breast cancer (BC) and ovarian cancer (OC) predisposition gene involved in the homologous recombination repair pathway. However, the prevalence and clinicopathological association of PALB2 pathogenic/likely pathogenic (PV/LPV) variants in Middle East is still not fully explored. Total 918 BC/OC patients from Saudi Arabia were selected for PALB2 mutations screening using capture sequencing technology. Five heterozygous PVs or LPVs were identified in six cases, accounting for 0.65% (6/918) of entire cohort. Two cases (33.3%) harbored PVs and four cases (66.7%) carried LPVs. Four PVs/LPVs (80%) were frameshift along with one novel splicing LPV (c.2835-2_2835-1delinsTT). One recurrent LPV (c.3425delT: p.L1142fs) was identified in two cases. All six affected carriers have breast cancer diagnosis with median age of 39.5 years (range 34-49 years). Only two cases (33%) have documented family history of cancer. Breast cancer phenotype was invasive ductal unilateral cancer in all cases with 66.7% of hormone receptor positive and 16% of triple negative tumors. Germline PVs/LPVs in the PALB2 gene were observed in low frequency of 0.65% in Saudi BC and/or OC. Our study confirms one recurrent LPV and one novel LPV in Saudi breast cancer patients.
Collapse
Affiliation(s)
- Abdul K Siraj
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
| | - Rong Bu
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
| | - Sandeep Kumar Parvathareddy
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
| | - Kaleem Iqbal
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
| | - Saud Azam
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
| | - Zeeshan Qadri
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
| | - Maha Al-Rasheed
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
| | - Wael Haqawi
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
| | - Mark Diaz
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
| | - Ingrid G Victoria
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia
| | - Ismail A Al-Badawi
- Department of Obstetrics-Gynecology, King Faisal Specialist Hospital and Research Center, Riyadh, 11211, Saudi Arabia
| | - Asma Tulbah
- Department of Pathology, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia
| | - Fouad Al-Dayel
- Department of Pathology, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia
| | - Dahish Ajarim
- Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia
| | - Khawla S Al-Kuraya
- Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.
| |
Collapse
|
3
|
Fierheller CT, Alenezi WM, Serruya C, Revil T, Amuzu S, Bedard K, Subramanian DN, Fewings E, Bruce JP, Prokopec S, Bouchard L, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Tischkowitz M, Campbell IG, Pugh TJ, Greenwood CMT, Ragoussis J, Tonin PN. Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. Genes (Basel) 2023; 14:genes14020277. [PMID: 36833203 PMCID: PMC9956348 DOI: 10.3390/genes14020277] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 01/11/2023] [Accepted: 01/16/2023] [Indexed: 01/26/2023] Open
Abstract
FANCI was recently identified as a new candidate ovarian cancer (OC)-predisposing gene from the genetic analysis of carriers of FANCI c.1813C>T; p.L605F in OC families. Here, we aimed to investigate the molecular genetic characteristics of FANCI, as they have not been described in the context of cancer. We first investigated the germline genetic landscape of two sisters with OC from the discovery FANCI c.1813C>T; p.L605F family (F1528) to re-affirm the plausibility of this candidate. As we did not find other conclusive candidates, we then performed a candidate gene approach to identify other candidate variants in genes involved in the FANCI protein interactome in OC families negative for pathogenic variants in BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, and FANCI, which identified four candidate variants. We then investigated FANCI in high-grade serous ovarian carcinoma (HGSC) from FANCI c.1813C>T carriers and found evidence of loss of the wild-type allele in tumour DNA from some of these cases. The somatic genetic landscape of OC tumours from FANCI c.1813C>T carriers was investigated for mutations in selected genes, copy number alterations, and mutational signatures, which determined that the profiles of tumours from carriers were characteristic of features exhibited by HGSC cases. As other OC-predisposing genes such as BRCA1 and BRCA2 are known to increase the risk of other cancers including breast cancer, we investigated the carrier frequency of germline FANCI c.1813C>T in various cancer types and found overall more carriers among cancer cases compared to cancer-free controls (p = 0.007). In these different tumour types, we also identified a spectrum of somatic variants in FANCI that were not restricted to any specific region within the gene. Collectively, these findings expand on the characteristics described for OC cases carrying FANCI c.1813C>T; p.L605F and suggest the possible involvement of FANCI in other cancer types at the germline and/or somatic level.
Collapse
Affiliation(s)
- Caitlin T. Fierheller
- Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada
- Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | - Wejdan M. Alenezi
- Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada
- Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
- Department of Medical Laboratory Technology, Taibah University, Medina 42353, Saudi Arabia
| | - Corinne Serruya
- Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | - Timothée Revil
- Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada
- McGill Genome Centre, McGill University, Montreal, QC H3A 0G1, Canada
| | - Setor Amuzu
- Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada
- McGill Genome Centre, McGill University, Montreal, QC H3A 0G1, Canada
| | - Karine Bedard
- Laboratoire de Diagnostic Moléculaire, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada
- Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montreal, QC H3T 1J4, Canada
| | - Deepak N. Subramanian
- Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
| | - Eleanor Fewings
- Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge CB2 1TN, UK
| | - Jeffrey P. Bruce
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada
| | - Stephenie Prokopec
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada
| | - Luigi Bouchard
- Department of Biochemistry and Functional Genomics, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada
- Department of Medical Biology, Centres Intégrés Universitaires de Santé et de Services Sociaux du Saguenay-Lac-Saint-Jean Hôpital Universitaire de Chicoutimi, Saguenay, QC G7H 7K9, Canada
- Centre de Recherche du Centre Hospitalier l’Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada
| | - Diane Provencher
- Centre de Recherche du Centre Hospitalier de l’Université de Montréal and Institut du Cancer de Montréal, Montreal, QC H2X 0A9, Canada
- Division of Gynecologic Oncology, Université de Montréal, Montreal, QC H3T 1J4, Canada
| | - William D. Foulkes
- Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada
- Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
- Department of Medicine, McGill University, Montreal, QC H3G 2M1, Canada
| | - Zaki El Haffaf
- Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, QC H2X 0A9, Canada
| | - Anne-Marie Mes-Masson
- Centre de Recherche du Centre Hospitalier de l’Université de Montréal and Institut du Cancer de Montréal, Montreal, QC H2X 0A9, Canada
- Department of Medicine, Université de Montréal, Montreal, QC H3T 1J4, Canada
| | - Marc Tischkowitz
- Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge CB2 1TN, UK
| | - Ian G. Campbell
- Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3010, Australia
| | - Trevor J. Pugh
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada
| | - Celia M. T. Greenwood
- Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
- Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H4A 3T2, Canada
- Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, QC H3A 1Y7, Canada
| | - Jiannis Ragoussis
- Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada
- McGill Genome Centre, McGill University, Montreal, QC H3A 0G1, Canada
| | - Patricia N. Tonin
- Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada
- Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
- Department of Medicine, McGill University, Montreal, QC H3G 2M1, Canada
- Correspondence:
| |
Collapse
|
4
|
Piedmonte S, Tsang K, Jembere N, Murphy J, McCurdy B, Sacco J, Kupets R. Are Women with Antecedent Low-Grade Cytology and <CIN2 Findings in Colposcopy Being Overmanaged? JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA 2022; 44:1054-1060. [PMID: 35948169 DOI: 10.1016/j.jogc.2022.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 05/31/2022] [Accepted: 06/01/2022] [Indexed: 10/15/2022]
Abstract
OBJECTIVE To determine the baseline and cumulative risks of cervical intraepithelial lesion grade 3 (CIN3) and invasive cervical cancer in patients with <CIN2 colposcopy findings after a low-grade screening cytology finding (atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion [LSIL]). METHODS By linking administrative databases, including cytology, pathology, cancer registries, and physician billing history, a population-based cohort study was performed on participants with <CIN2 initial colposcopy results after a low-grade antecedent cytology finding, between January 2012 and December 2013. Three and 5-year risks of CIN3 and invasive cervical cancer were generated using Kaplan-Meier survival analysis. RESULTS Among the 36 887 participants included in the study, CIN3 incidence based on referral cytology were as follows at 3 and 5 years, respectively: normal, 0.7% and 0.9%; ASCUS, 4.31% and 5.6%; and LSIL, 5.9% and 7.2%. Three- and 5-year incidence of invasive cancer were 0% and 0.02% for normal cytology, 0.08% and 0.11% for ASCUS, and 0.04% and 0.07% for LSIL, respectively. Stratifying risk by biopsy result at initial colposcopy, 3- and 5-year CIN3 incidences were 2.85% and 3.81% with a negative biopsy, 7.09% and 8.32% with an LSIL biopsy, and 4.11% and 5.2% when no biopsy was done, respectively. Three- and 5-year incidence of invasive cancer was 0% and 0.05% after a negative biopsy, 0% and 0% after LSIL biopsy, and 0.05% and 0.08% when no biopsy was done, respectively. CONCLUSION When initial colposcopy is done after a low-grade screening cytology result and <CIN2 is identified, the risk of CIN3 and invasive cancer is low, particularly when biopsies indicate LSIL. Surveillance strategies should balance the likelihood of detecting CIN3 with the potential harms over management with too frequent screening or colposcopic interventions in low-risk patients.
Collapse
Affiliation(s)
- Sabrina Piedmonte
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON
| | | | | | | | | | | | | |
Collapse
|
5
|
Low BRCA1/2 germline mutation rate in a French-Canadian population with a diagnosis of epithelial tubo-ovarian carcinoma. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA 2022; 44:1047-1053. [PMID: 35779836 DOI: 10.1016/j.jogc.2022.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 05/31/2022] [Accepted: 06/01/2022] [Indexed: 11/20/2022]
|
6
|
The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population. Cancers (Basel) 2022; 14:cancers14092251. [PMID: 35565380 PMCID: PMC9104874 DOI: 10.3390/cancers14092251] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Revised: 04/13/2022] [Accepted: 04/20/2022] [Indexed: 12/03/2022] Open
Abstract
To identify candidate variants in RAD51C and RAD51D ovarian cancer (OC) predisposing genes by investigating French Canadians (FC) exhibiting unique genetic architecture. Candidates were identified by whole exome sequencing analysis of 17 OC families and 53 early-onset OC cases. Carrier frequencies were determined by the genetic analysis of 100 OC or HBOC families, 438 sporadic OC cases and 1025 controls. Variants of unknown function were assayed for their biological impact and/or cellular sensitivity to olaparib. RAD51C c.414G>C;p.Leu138Phe and c.705G>T;p.Lys235Asn and RAD51D c.137C>G;p.Ser46Cys, c.620C>T;p.Ser207Leu and c.694C>T;p.Arg232Ter were identified in 17.6% of families and 11.3% of early-onset cases. The highest carrier frequency was observed in OC families (1/44, 2.3%) and sporadic cases (15/438, 3.4%) harbouring RAD51D c.620C>T versus controls (1/1025, 0.1%). Carriers of c.620C>T (n = 7), c.705G>T (n = 2) and c.137C>G (n = 1) were identified in another 538 FC OC cases. RAD51C c.705G>T affected splicing by skipping exon four, while RAD51D p.Ser46Cys affected protein stability and conferred olaparib sensitivity. Genetic and functional assays implicate RAD51C c.705G>T and RAD51D c.137C>G as likely pathogenic variants in OC. The high carrier frequency of RAD51D c.620C>T in FC OC cases validates previous findings. Our findings further support the role of RAD51C and RAD51D in hereditary OC.
Collapse
|
7
|
Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, Bedard K, Arcand SL, Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, Bruce JP, Bell R, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Majewski J, Pugh TJ, Tischkowitz M, James PA, Campbell IG, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. Genome Med 2021; 13:186. [PMID: 34861889 PMCID: PMC8642877 DOI: 10.1186/s13073-021-00998-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Accepted: 10/27/2021] [Indexed: 12/14/2022] Open
Abstract
Background Familial ovarian cancer (OC) cases not harbouring pathogenic variants in either of the BRCA1 and BRCA2 OC-predisposing genes, which function in homologous recombination (HR) of DNA, could involve pathogenic variants in other DNA repair pathway genes. Methods Whole exome sequencing was used to identify rare variants in HR genes in a BRCA1 and BRCA2 pathogenic variant negative OC family of French Canadian (FC) ancestry, a population exhibiting genetic drift. OC cases and cancer-free individuals from FC and non-FC populations were investigated for carrier frequency of FANCI c.1813C>T; p.L605F, the top-ranking candidate. Gene and protein expression were investigated in cancer cell lines and tissue microarrays, respectively. Results In FC subjects, c.1813C>T was more common in familial (7.1%, 3/42) than sporadic (1.6%, 7/439) OC cases (P = 0.048). Carriers were detected in 2.5% (74/2950) of cancer-free females though female/male carriers were more likely to have a first-degree relative with OC (121/5249, 2.3%; Spearman correlation = 0.037; P = 0.011), suggesting a role in risk. Many of the cancer-free females had host factors known to reduce risk to OC which could influence cancer risk in this population. There was an increased carrier frequency of FANCI c.1813C>T in BRCA1 and BRCA2 pathogenic variant negative OC families, when including the discovery family, compared to cancer-free females (3/23, 13%; OR = 5.8; 95%CI = 1.7–19; P = 0.005). In non-FC subjects, 10 candidate FANCI variants were identified in 4.1% (21/516) of Australian OC cases negative for pathogenic variants in BRCA1 and BRCA2, including 10 carriers of FANCI c.1813C>T. Candidate variants were significantly more common in familial OC than in sporadic OC (P = 0.04). Localization of FANCD2, part of the FANCI-FANCD2 (ID2) binding complex in the Fanconi anaemia (FA) pathway, to sites of induced DNA damage was severely impeded in cells expressing the p.L605F isoform. This isoform was expressed at a reduced level, destabilized by DNA damaging agent treatment in both HeLa and OC cell lines, and exhibited sensitivity to cisplatin but not to a poly (ADP-ribose) polymerase inhibitor. By tissue microarray analyses, FANCI protein was consistently expressed in fallopian tube epithelial cells and only expressed at low-to-moderate levels in 88% (83/94) of OC samples. Conclusions This is the first study to describe candidate OC variants in FANCI, a member of the ID2 complex of the FA DNA repair pathway. Our data suggest that pathogenic FANCI variants may modify OC risk in cancer families. Supplementary Information The online version contains supplementary material available at 10.1186/s13073-021-00998-5.
Collapse
Affiliation(s)
- Caitlin T Fierheller
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada.,Cancer Research Program, Centre for Translational Biology, The Research Institute of the McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3 J1, Canada
| | - Laure Guitton-Sert
- Genome Stability Laboratory, CHU de Québec-Université Laval Research Center, Oncology Division, Quebec City, Quebec, Canada.,Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Quebec City, Quebec, Canada
| | - Wejdan M Alenezi
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada.,Cancer Research Program, Centre for Translational Biology, The Research Institute of the McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3 J1, Canada.,Department of Medical Laboratory Technology, Taibah University, Medina, Saudi Arabia
| | - Timothée Revil
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada.,McGill Genome Centre, McGill University, Montreal, Quebec, Canada
| | - Kathleen K Oros
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| | - Yuandi Gao
- Genome Stability Laboratory, CHU de Québec-Université Laval Research Center, Oncology Division, Quebec City, Quebec, Canada.,Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Quebec City, Quebec, Canada
| | - Karine Bedard
- Laboratoire de Diagnostic Moléculaire, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.,Département de pathologie et biologie cellulaire, Université de Montréal, Montreal, Quebec, Canada
| | - Suzanna L Arcand
- Cancer Research Program, Centre for Translational Biology, The Research Institute of the McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3 J1, Canada
| | - Corinne Serruya
- Cancer Research Program, Centre for Translational Biology, The Research Institute of the McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3 J1, Canada
| | - Supriya Behl
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada
| | - Liliane Meunier
- Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
| | - Hubert Fleury
- Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
| | - Eleanor Fewings
- Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK
| | - Deepak N Subramanian
- Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Javad Nadaf
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada.,McGill Genome Centre, McGill University, Montreal, Quebec, Canada
| | - Jeffrey P Bruce
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Rachel Bell
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Diane Provencher
- Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada.,Division of Gynecologic Oncology, Université de Montréal, Montreal, Quebec, Canada
| | - William D Foulkes
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada.,Cancer Research Program, Centre for Translational Biology, The Research Institute of the McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3 J1, Canada.,Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.,Department of Medicine, McGill University, Montreal, Quebec, Canada
| | - Zaki El Haffaf
- Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
| | - Anne-Marie Mes-Masson
- Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada.,Department of Medicine, Université de Montréal, Montreal, Quebec, Canada
| | - Jacek Majewski
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada
| | - Trevor J Pugh
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.,Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Marc Tischkowitz
- Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK
| | - Paul A James
- Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.,The Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Ian G Campbell
- Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
| | - Celia M T Greenwood
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada.,Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.,Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.,Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Quebec, Canada
| | - Jiannis Ragoussis
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada.,McGill Genome Centre, McGill University, Montreal, Quebec, Canada
| | - Jean-Yves Masson
- Genome Stability Laboratory, CHU de Québec-Université Laval Research Center, Oncology Division, Quebec City, Quebec, Canada.,Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Quebec City, Quebec, Canada
| | - Patricia N Tonin
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada. .,Cancer Research Program, Centre for Translational Biology, The Research Institute of the McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec, H4A 3 J1, Canada. .,Department of Medicine, McGill University, Montreal, Quebec, Canada.
| |
Collapse
|
8
|
The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families. Cancers (Basel) 2021; 13:cancers13143406. [PMID: 34298626 PMCID: PMC8305212 DOI: 10.3390/cancers13143406] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 06/23/2021] [Accepted: 06/24/2021] [Indexed: 12/19/2022] Open
Abstract
The French Canadian population of the province of Quebec has been recognized for its contribution to research in medical genetics, especially in defining the role of heritable pathogenic variants in cancer predisposing genes. Multiple carriers of a limited number of pathogenic variants in BRCA1 and BRCA2, the major risk genes for hereditary breast and/or ovarian cancer syndrome families, have been identified in French Canadians, which is in stark contrast to the array of over 2000 different pathogenic variants reported in each of these genes in other populations. As not all such cancer syndrome families are explained by BRCA1 and BRCA2, newly proposed gene candidates identified in other populations have been investigated for their role in conferring risk in French Canadian cancer families. For example, multiple carriers of distinct variants were identified in PALB2 and RAD51D. The unique genetic architecture of French Canadians has been attributed to shared ancestry due to common ancestors of early settlers of this population with origins mainly from France. In this review, we discuss the merits of genetically characterizing cancer predisposing genes in French Canadians of Quebec. We focused on genes that have been implicated in hereditary breast and/or ovarian cancer syndrome families as they have been the most thoroughly characterized cancer syndromes in this population. We describe how genetic analyses of French Canadians have facilitated: (i) the classification of variants in BRCA1 and BRCA2; (ii) the identification and classification of variants in newly proposed breast and/or ovarian cancer predisposing genes; and (iii) the identification of a new breast cancer predisposing gene candidate, RECQL. The genetic architecture of French Canadians provides a unique opportunity to evaluate new candidate cancer predisposing genes regardless of the population in which they were identified.
Collapse
|
9
|
Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease. Cancers (Basel) 2020; 12:cancers12082222. [PMID: 32784519 PMCID: PMC7465288 DOI: 10.3390/cancers12082222] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2020] [Revised: 08/04/2020] [Accepted: 08/05/2020] [Indexed: 12/30/2022] Open
Abstract
Cancer cell lines are amongst the most important pre-clinical models. In the context of epithelial ovarian cancer, a highly heterogeneous disease with diverse subtypes, it is paramount to study a wide panel of models in order to draw a representative picture of the disease. As this lethal gynaecological malignancy has seen little improvement in overall survival in the last decade, it is all the more pressing to support future research with robust and diverse study models. Here, we describe ten novel spontaneously immortalized patient-derived ovarian cancer cell lines, detailing their respective mutational profiles and gene/biomarker expression patterns, as well as their in vitro and in vivo growth characteristics. Eight of the cell lines were classified as high-grade serous, while two were determined to be of the rarer mucinous and clear cell subtypes, respectively. Each of the ten cell lines presents a panel of characteristics reflective of diverse clinically relevant phenomena, including chemotherapeutic resistance, metastatic potential, and subtype-associated mutations and gene/protein expression profiles. Importantly, four cell lines formed subcutaneous tumors in mice, a key characteristic for pre-clinical drug testing. Our work thus contributes significantly to the available models for the study of ovarian cancer, supplying additional tools to better understand this complex disease.
Collapse
|
10
|
Alenezi WM, Fierheller CT, Recio N, Tonin PN. Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers. Genes (Basel) 2020; 11:E856. [PMID: 32726901 PMCID: PMC7464855 DOI: 10.3390/genes11080856] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 07/22/2020] [Accepted: 07/23/2020] [Indexed: 12/19/2022] Open
Abstract
Soon after the discovery of BRCA1 and BRCA2 over 20 years ago, it became apparent that not all hereditary breast and/or ovarian cancer syndrome families were explained by germline variants in these cancer predisposing genes, suggesting that other such genes have yet to be discovered. BRCA1-associated ring domain (BARD1), a direct interacting partner of BRCA1, was one of the earliest candidates investigated. Sequencing analyses revealed that potentially pathogenic BARD1 variants likely conferred a low-moderate risk to hereditary breast cancer, but this association is inconsistent. Here, we review studies of BARD1 as a cancer predisposing gene and illustrate the challenge of discovering additional cancer risk genes for hereditary breast and/or ovarian cancer. We selected peer reviewed research articles that focused on three themes: (i) sequence analyses of BARD1 to identify potentially pathogenic germline variants in adult hereditary cancer syndromes; (ii) biological assays of BARD1 variants to assess their effect on protein function; and (iii) association studies of BARD1 variants in family-based and case-control study groups to assess cancer risk. In conclusion, BARD1 is likely to be a low-moderate penetrance breast cancer risk gene.
Collapse
Affiliation(s)
- Wejdan M. Alenezi
- Department of Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada; (W.M.A.); (C.T.F.); (N.R.)
- Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
- Department of Medical Laboratory Technology, Taibah University, Medina 42353, Saudi Arabia
| | - Caitlin T. Fierheller
- Department of Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada; (W.M.A.); (C.T.F.); (N.R.)
- Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | - Neil Recio
- Department of Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada; (W.M.A.); (C.T.F.); (N.R.)
- Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | - Patricia N. Tonin
- Department of Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada; (W.M.A.); (C.T.F.); (N.R.)
- Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada
- Department of Medicine, McGill University, Montreal, QC H3A 0G4, Canada
| |
Collapse
|
11
|
Wappenschmidt B, Hauke J, Faust U, Niederacher D, Wiesmüller L, Schmidt G, Groß E, Gehrig A, Sutter C, Ramser J, Rump A, Arnold N, Meindl A. Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer. Geburtshilfe Frauenheilkd 2020; 80:410-429. [PMID: 32322110 PMCID: PMC7174002 DOI: 10.1055/a-1110-0909] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 01/28/2020] [Accepted: 01/29/2020] [Indexed: 12/14/2022] Open
Abstract
More than ten years ago, the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) set up a panel of experts (VUS Task Force) which was tasked with reviewing the classifications of genetic variants reported by individual centres of the GC-HBOC to the central database in Leipzig and reclassifying them, where necessary, based on the most recent data. When it evaluates variants, the VUS Task Force must arrive at a consensus. The resulting classifications are recorded in a central database where they serve as a basis for ensuring the consistent evaluation of previously known and newly identified variants in the different centres of the GC-HBOC. The standardised VUS evaluation by the VUS Task Force is a key element of the recall system which has also been set up by the GC-HBOC. The system will be used to pass on information to families monitored and managed by GC-HBOC centres in the event that previously classified variants are reclassified based on new information. The evaluation algorithm of the VUS Task Force was compiled using internationally established assessment methods (IARC, ACMG, ENIGMA) and is presented here together with the underlying evaluation criteria used to arrive at the classification decision using a flow chart. In addition, the characteristics and special features of specific individual risk genes associated with breast and/or ovarian cancer are discussed in separate subsections. The URLs of relevant databases have also been included together with extensive literature references to provide additional information and cover the scope and dynamism of the current state of knowledge on the evaluation of genetic variants. In future, if criteria are updated based on new information, the update will be published on the website of the GC-HBOC (
https://www.konsortium-familiaerer-brustkrebs.de/
).
Collapse
Affiliation(s)
- Barbara Wappenschmidt
- Zentrum familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln, Germany
| | - Jan Hauke
- Zentrum familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln, Germany
| | - Ulrike Faust
- Institut für Medizinische Genetik und Angewandte Genomik, Universität Tübingen, Tübingen, Germany
| | - Dieter Niederacher
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
| | - Lisa Wiesmüller
- Frauenklinik, Sektion Gynäkologische Onkologie, Uniklinik Ulm, Ulm, Germany
| | - Gunnar Schmidt
- Institut für Humangenetik, Medizinische Hochschule Hannover, Hannover, Germany
| | - Evi Groß
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Campus Großhadern, München, Germany
| | - Andrea Gehrig
- Institut für Humangenetik, Universität Würzburg, Würzburg, Germany
| | - Christian Sutter
- Institut für Humangenetik, Universität Heidelberg, Heidelberg, Germany
| | - Juliane Ramser
- Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, München, Germany
| | - Andreas Rump
- Institut für klinische Genetik, Technische Universität Dresden, Dresden, Germany
| | - Norbert Arnold
- Universitätsklinikum Kiel, Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany.,Institut für Klinische Molekularbiologie, Universitätsklinikum Kiel, Kiel, Germany
| | - Alfons Meindl
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Campus Großhadern, München, Germany.,Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, München, Germany
| |
Collapse
|
12
|
Behl S, Hamel N, de Ladurantaye M, Lepage S, Lapointe R, Mes-Masson AM, Foulkes WD. Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls. Sci Rep 2020; 10:6491. [PMID: 32300229 PMCID: PMC7162921 DOI: 10.1038/s41598-020-63100-w] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 03/21/2020] [Indexed: 11/08/2022] Open
Abstract
Inherited germline pathogenic variants are responsible for ~5% of breast cancer globally. Through rapid expansion and isolation since immigration in the early 17th century, French Canadians are a relatively genetically homogenous founder population and therefore represent a unique demographic for genetic contributions to disease. To date, twenty variants in BRCA1, BRCA2, and PALB2 that predispose families to breast and ovarian cancer have been identified as recurring in the French-Canadian founder population. Our objective was to evaluate the clinical efficacy and validity of targeted genetic testing for these variants in Montreal French Canadians. A total of 555 breast cancer cases unselected for family history or age of diagnosis were genotyped, along with 1940 controls without a personal or family history of cancer. A Sequenom genotyping assay identified a pathogenic variant in 0.2% (5 of 1940) of cancer-free controls, and 3.8% (21/555) of breast cancer cases. Almost 10% (12/113) of early onset cases were heterozygous for founder BRCA1 or BRCA2 pathogenic variant. Of twenty variants tested, only seven were identified in this study. The option of providing this test as population-based screening is discussed.
Collapse
Affiliation(s)
- Supriya Behl
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada
| | - Nancy Hamel
- Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
| | - Manon de Ladurantaye
- Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
| | - Stéphanie Lepage
- Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
- Department of Medicine, Université de Montréal, Montreal, Canada
- Institut du cancer de Montréal, Montréal, Québec, Canada
| | - Réjean Lapointe
- Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
- Department of Medicine, Université de Montréal, Montreal, Canada
- Institut du cancer de Montréal, Montréal, Québec, Canada
| | - Anne-Marie Mes-Masson
- Centre de recherche du Centre hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
- Department of Medicine, Université de Montréal, Montreal, Canada
| | - William D Foulkes
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
- Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Medical Genetics, Jewish General Hospital, Montreal, Quebec, Canada.
| |
Collapse
|
13
|
Smith AL, Wong C, Cuggia A, Borgida A, Holter S, Hall A, Connor AA, Bascuñana C, Asselah J, Bouganim N, Poulin V, Jolivet J, Vafiadis P, Le P, Martel G, Lemay F, Beaudoin A, Rafatzand K, Chaudhury P, Barkun J, Metrakos P, Marcus V, Omeroglu A, Chong G, Akbari MR, Foulkes WD, Gallinger S, Zogopoulos G. Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries. JCO Precis Oncol 2018; 2:1-16. [DOI: 10.1200/po.17.00098] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Purpose We investigated the translational value of reflex testing for germline mutations in four homology-directed DNA repair predisposition genes ( BRCA1, BRCA2, PALB2, and ATM) in consecutive patients with pancreatic adenocarcinoma. Methods One hundred fifty patients with French-Canadian (FC) ancestry were evaluated for founder mutations, and 114 patients were subsequently assessed by full gene sequencing and multiplex ligation-dependent probe amplification for nonfounder mutations. Two hundred thirty-six patients unselected for ancestry were also assessed for mutations by full gene sequencing. Results The FC founder mutation prevalence among the 150 patients was 5.3% (95% CI, 2.6% to 10.3%), and the nonfounder mutation prevalence across the four genes among the 114 patients tested was 2.6% (95% CI, 0.6% to 7.8%). In the case series unselected for ancestry, 10.0% (95% CI, 2.7% to 26.4%) of patients reporting Ashkenazi Jewish (AJ) ancestry carried an AJ founder mutation, with no nonfounder mutations identified. The mutation prevalence among patients without FC/AJ ancestry was 4.9% (95% CI, 2.6% to 8.8%). Mutations were more frequent in patients diagnosed at ≤ 50 years of age ( P = .03) and in patients with either two or more first- or second-degree relatives with pancreas, breast, ovarian or prostate cancer, or one such relative and a second primary of one of these cancer types ( P < .001). BRCA1, BRCA2, and PALB2 carriers with late-stage (III or IV) disease had an overall survival advantage ( P = .049), particularly if treated with platinum-based chemotherapies ( P = .030). Conclusion Considering these results, we recommend reflex founder mutation testing of patients with FC/AJ ancestry and full gene sequencing of patients who are ≤ 50 years or meet the identified family history criteria. Reflex testing of all incident patients for these four genes may become justified as full gene sequencing costs decline.
Collapse
Affiliation(s)
- Alyssa L. Smith
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Cavin Wong
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Adeline Cuggia
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Ayelet Borgida
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Spring Holter
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Anita Hall
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Ashton A. Connor
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Claire Bascuñana
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Jamil Asselah
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Nathaniel Bouganim
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Véronique Poulin
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Jacques Jolivet
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Petro Vafiadis
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Philippe Le
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Guillaume Martel
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Frédéric Lemay
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Annie Beaudoin
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Khashayar Rafatzand
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Prosanto Chaudhury
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Jeffrey Barkun
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Peter Metrakos
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Victoria Marcus
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Atilla Omeroglu
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - George Chong
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Mohammad R. Akbari
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - William D. Foulkes
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - Steven Gallinger
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| | - George Zogopoulos
- Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, and George Zogopoulos, Goodman Cancer Research Centre, McGill University; Alyssa L. Smith, Cavin Wong, Adeline Cuggia, Anita Hall, Claire Bascuñana, Peter Metrakos, William D. Foulkes, and George Zogopoulos, Research Institute of the McGill University Health Centre; Jamil Asselah, Nathaniel Bouganim, Khashayar Rafatzand, Prosanto Chaudhury, Jeffrey Barkun, Peter Metrakos, Victoria Marcus, Atilla Omeroglu, William D. Foulkes, and
| |
Collapse
|
14
|
PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland. BMC Med Genomics 2017; 10:14. [PMID: 28279176 PMCID: PMC5345197 DOI: 10.1186/s12920-017-0251-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Accepted: 03/03/2017] [Indexed: 12/20/2022] Open
Abstract
Background The PALB2 gene encodes a protein that plays a crucial role in maintaining genomic integrity. Germline inactivating mutations in PALB2 are associated with an increased risk of breast and ovarian cancer. The prevalence and spectrum of recurrent PALB2 germline mutations in breast and ovarian cancer patients from Poland is not clearly defined. Methods PALB2 exons were amplified from 460 BRCA1/2-mutation negative women with familial breast and/or ovarian cancer and early-onset breast cancer using AmpliSeq technology and sequenced on an Ion Torrent PGM sequencer. In addition, eight selected variants were genotyped using TaqMan assays in 807 BRCA1/2-mutation negative breast cancer patients and 1690 healthy women. Results Two recurrent PALB2 mutations, c.172_175delTTGT and c.509_510delGA, were identified, along with one novel mutation, c.347insT. In total, PALB2 pathogenic mutations were detected in 7/460 (1.5%) patients. Furthermore, in breast and/or ovarian cancer patients, several single nucleotide variants (SNVs) were detected in the PALB2 coding region. In an additional group of 807 patients, eight (1%) carriers of two pathogenic mutations, c.172_175delTTGT (0.5%) and c.509_510delGA (0.5%), were identified. The c.509_510delGA mutation was not identified in healthy controls, while c.172_175delTTGT was identified in 4/1690 (0.24%) of control women. Conclusions Germline mutations in the PALB2 gene were observed at a frequency of approximately 1.5% in Polish breast and/or ovarian cancer patients. Our study confirms two recurrent PALB2 mutations; c.172_175delGA and c.509_510delGA.
Collapse
|
15
|
Poumpouridou N, Goutas N, Tsionou C, Dimas K, Lianidou E, Kroupis C. Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer. Fam Cancer 2015; 15:183-91. [PMID: 26573693 DOI: 10.1007/s10689-015-9851-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Beyond BRCA1 and BRCA2 genes, PALB2 (Partner and localizer of BRCA2) emerges as the third breast cancer susceptibility gene due to its role in the same DNA repair pathway: homologous recombination. In most populations studied so far, PALB2 mutations are detected in 1-2% of BRCA negative female patients. PALB2 gene contains 13 exons; exons 4 and 5 consist 65% of the coding area. We developed a protein truncation test (PTT) for quick screening of truncating pathogenic mutations of these two large exons. Specific primers were de novo, in silico designed and the PTT-PCR products were translated in the presence of biotinylated lysine and detected colorimetrically. The assay was initially tested in 30 patients with hereditary breast cancer, negative for BRCA mutations and then, in 17 patients with the rare medullary breast cancer subtype. Small PALB2 exons were screened with high-resolution melting curve analysis (HRMA) and the large DNA rearrangements with multiplex ligation-dependent probe amplification (MLPA). Any alterations detected were verified by Sanger DNA Sequencing. The developed PTT methodology is highly specific for clinical significant mutations; positive control samples that produce truncated PALB2 peptides were correctly identified and the method was accurate when compared to DNA sequencing. We did not detect any deleterious PALB2 mutation in both groups of patients. HRMA and MLPA were also negative for all tested samples. However, our novel, fast and cost-effective PTT method for pathogenic mutation detection of the two large PALB2 exons can be applied in screening of a large number of breast cancer patients.
Collapse
Affiliation(s)
- Nikoleta Poumpouridou
- Department of Clinical Biochemistry, Attikon University General Hospital, University of Athens Medical School, 1 Rimini St., 12462, Haidari, Greece.,Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, 15771, Athens, Greece
| | - Nikolaos Goutas
- Laboratory of Pathologic Anatomy, Evgenidio Hospital, University of Athens Medical School, 15128, Athens, Greece
| | - Christina Tsionou
- Breast Cancer Unit, Mitera Maternity and Surgery Hospital, 15123, Maroussi, Greece
| | - Kleanthi Dimas
- Department of Clinical Biochemistry, Attikon University General Hospital, University of Athens Medical School, 1 Rimini St., 12462, Haidari, Greece
| | - Evi Lianidou
- Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, 15771, Athens, Greece
| | - Christos Kroupis
- Department of Clinical Biochemistry, Attikon University General Hospital, University of Athens Medical School, 1 Rimini St., 12462, Haidari, Greece.
| |
Collapse
|
16
|
Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet 2015; 47:643-6. [PMID: 25915596 DOI: 10.1038/ng.3284] [Citation(s) in RCA: 151] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Accepted: 03/30/2015] [Indexed: 01/01/2023]
Abstract
Several moderate- and high-risk breast cancer susceptibility genes have been discovered, but more are likely to exist. To discover new breast cancer susceptibility genes, we used 2 populations (from Poland and Quebec, Canada) and applied whole-exome sequencing in a discovery phase (n = 195), followed by validation. We identified rare recurrent RECQL mutations in each population. In Quebec, 7 of 1,013 higher-risk breast cancer cases and 1 of 7,136 newborns carried the c.634C>T (p.Arg215*) variant (P = 0.00004). In Poland, 30 of 13,136 unselected breast cancer cases and 2 of 4,702 controls carried the c.1667_1667+3delAGTA (p.K555delinsMYKLIHYSFR) variant (P = 0.008). RECQL is implicated in resolving stalled DNA replication forks to prevent double-stranded DNA (dsDNA) breaks. This function is related to that of other known breast cancer susceptibility genes, many of which are involved in repairing dsDNA breaks. We conclude that RECQL is a breast cancer susceptibility gene.
Collapse
|
17
|
Ancot F, Arcand SL, Mes-Masson AM, Provencher DM, Tonin PN. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. Oncol Lett 2015; 9:2787-2790. [PMID: 26137147 DOI: 10.3892/ol.2015.3123] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Accepted: 02/10/2015] [Indexed: 01/11/2023] Open
Abstract
French Canadian families with breast cancer and breast-ovarian cancer syndrome harbor specific BRCA1, BRCA2 and PALB2 germline mutations, which have been attributed to common founders. Mutations in these genes confer an increased risk to breast and ovarian cancers, and have been identified to play a role in and directly interact with the common homologous recombination DNA repair pathways. Our previous study described the case of a female diagnosed with breast cancer at 45 years old, who harbored the PALB2:c.2323C>T [p.Q775X] and BRCA2:c.9004G>A [p.E3002K] germline mutations, which have been found to recur in the French Canadian cancer families. As the frequency of double heterozygous carriers of breast-ovarian cancer susceptibility alleles is unknown, and due to the possibility that there may be implications for genetic counseling and management for these carriers, the present study investigated the co-occurrence of BRCA1/BRCA2 and PALB2 mutations in the French Canadian cancer families. The PALB2:c.2323C>T [p.Q775X] mutation, which is the only PALB2 mutation to have been identified in French Canadian cancer families, was screened in 214 breast cancer cases and 22 breast-ovarian cancer cases from 114 BRCA1/BRCA2 mutation-positive French Canadian breast cancer (n=61) and breast-ovarian cancer (n=53) families using a tailored polymerase chain reaction-based TaqMan® SNP Genotyping Assay. No additional PALB2:c.2323C>T [p.Q775X] mutation carriers were identified among the BRCA1/BRCA2 mutation carriers. The results suggest that carriers of the PALB2:c.2323C>T [p.Q775X] mutation rarely co-occur in French Canadian breast cancer and breast-ovarian cancer families harboring BRCA1 or BRCA2 mutations.
Collapse
Affiliation(s)
- Frédéric Ancot
- Department of Human Genetics, McGill University, Montreal, QC H3G1A4, Canada
| | - Suzanna L Arcand
- Research Institute of The McGill University Health Centre, Montreal, QC H3G1A4, Canada
| | - Anne-Marie Mes-Masson
- Research Centre of The University of Montreal Hospital Centre/Montreal Cancer Institute, Montreal, QC H3G1A4, Canada ; Department of Medicine, Montreal, QC H3G1A4, Canada
| | - Diane M Provencher
- Research Centre of The University of Montreal Hospital Centre/Montreal Cancer Institute, Montreal, QC H3G1A4, Canada ; Division of Gynecological Oncology, Montreal, QC H3G1A4, Canada ; Department of Obstetrics and Gynecology, University of Montreal, Montreal, QC H3G1A4, Canada
| | - Patricia N Tonin
- Department of Human Genetics, McGill University, Montreal, QC H3G1A4, Canada ; Research Institute of The McGill University Health Centre, Montreal, QC H3G1A4, Canada ; Department of Medicine, McGill University, Montreal, QC H3G1A4, Canada
| |
Collapse
|
18
|
Leyton Y, Gonzalez-Hormazabal P, Blanco R, Bravo T, Fernandez-Ramires R, Morales S, Landeros N, Reyes JM, Peralta O, Tapia JC, Gomez F, Waugh E, Ibañez G, Pakomio J, Grau G, Jara L. Association of PALB2 sequence variants with the risk of familial and early-onset breast cancer in a South-American population. BMC Cancer 2015; 15:30. [PMID: 25636233 PMCID: PMC4323211 DOI: 10.1186/s12885-015-1033-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Accepted: 01/22/2015] [Indexed: 12/31/2022] Open
Abstract
Background Germline mutations in PALB2 have been identified in approximately 1% of familial breast cancer (BC) in several populations. Nevertheless its contribution in the South-American population is unknown. The goal of this study was to determine the prevalence of PALB2 mutations in the Chilean population. Methods 100 Chilean BRCA1/2-negatives familial BC cases were included for the PALB2 mutation analysis. We use conformational sensitive gel electrophoresis and direct sequencing. Using a case-control design, we studied the identified variants in 436 BC cases and 809 controls to evaluate their possible association with BC risk. Results No pathogenic mutations were detected. We identified three variants, the variant c.1861C > A not previously described was found in one of the 436 cases and none of the 809 controls. The bioinformatic analyses indicate that this variant probably is not pathogenic. PALB2 c.1676A > G (rs152451A/G) and c.2993C > T (rs45551636C/T) variants were significantly associated with increased BC risk only in cases with a strong family history of BC (OR = 1.9 [CI 95% 1.3-2.8] p < 0.01 and OR = 3.3 [CI 95% 1.4-7.3] p < 0.01, respectively). The rs152451A/G-rs45551636C/T composite genotype produce increase of the BC risk in cases with a strong family history of BC (OR = 3.6 [CI 95% 1.7-8.0] p = 0.003). The rs152451-G/rs45551636-C and rs152451-G/rs45551636-T haplotypes were associated with an increased BC risk only in cases with a strong family history of BC (OR = 1.6 [CI 95% 1.0-2.5] p = 0.05 and OR = 3.7 [CI 95% 1.8-7.5] p < 0.001, respectively). Conclusion Our results suggest that PALB2 c.1676A > G and c.2993C > T play roles in BC risk in women with a strong family history of BC. Electronic supplementary material The online version of this article (doi:10.1186/s12885-015-1033-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yessica Leyton
- Human Genetics Program, Institute of Biomedical Sciences (ICBM), School of Medicine, University of Chile, Av. Independencia 1027, Santiago, Chile.
| | - Patricio Gonzalez-Hormazabal
- Human Genetics Program, Institute of Biomedical Sciences (ICBM), School of Medicine, University of Chile, Av. Independencia 1027, Santiago, Chile.
| | - Rafael Blanco
- Human Genetics Program, Institute of Biomedical Sciences (ICBM), School of Medicine, University of Chile, Av. Independencia 1027, Santiago, Chile.
| | - Teresa Bravo
- National Cancer Society (Corporación Nacional del Cáncer -CONAC-), Santiago, Chile.
| | - Ricardo Fernandez-Ramires
- Research Institute in Dental Sciences, School of Odontology, University of Chile, Sergio Livingstone Pohlhammer 943, Santiago, Chile.
| | - Sebastian Morales
- Human Genetics Program, Institute of Biomedical Sciences (ICBM), School of Medicine, University of Chile, Av. Independencia 1027, Santiago, Chile.
| | - Natalia Landeros
- Human Genetics Program, Institute of Biomedical Sciences (ICBM), School of Medicine, University of Chile, Av. Independencia 1027, Santiago, Chile.
| | | | - Octavio Peralta
- Clínca Las Condes, Santiago, Chile. .,Department of Gyneacology and Obstetrics, School of Medicine, University of Chile, Av Santa Rosa 1234, Santiago, Chile.
| | - Julio C Tapia
- Cell Transformation Laboratory, Institute of Biomedical Sciences (ICBM), School of Medicine, Unversity of Chile, Av. Independencia 1027, Santiago, Chile.
| | | | | | - Gladys Ibañez
- Clínica Dávila, Av. Recoleta 464, Santiago, Chile. .,Hospital San José, San José 1196, Santiago, Chile.
| | - Janara Pakomio
- Human Genetics Program, Institute of Biomedical Sciences (ICBM), School of Medicine, University of Chile, Av. Independencia 1027, Santiago, Chile.
| | - Gilberto Grau
- Human Genetics Program, Institute of Biomedical Sciences (ICBM), School of Medicine, University of Chile, Av. Independencia 1027, Santiago, Chile.
| | - Lilian Jara
- Human Genetics Program, Institute of Biomedical Sciences (ICBM), School of Medicine, University of Chile, Av. Independencia 1027, Santiago, Chile.
| |
Collapse
|
19
|
Abstract
PALB2 [partner and localizer of BRCA2 (breast cancer early-onset 2)] [corrected] has emerged as a key player in the maintenance of genome integrity. Biallelic mutations in PALB2 cause FA (Fanconi's anaemia) subtype FA-N, a devastating inherited disorder marked by developmental abnormalities, bone marrow failure and childhood cancer susceptibility, whereas monoallelic mutations predispose to breast, ovarian and pancreatic cancer. The tumour suppressor role of PALB2 has been intimately linked to its ability to promote HR (homologous recombination)-mediated repair of DNA double-strand breaks. Because PALB2 lies at the crossroads between FA, HR and cancer susceptibility, understanding its function has become the primary focus of several studies. The present review discusses a current synthesis of the contribution of PALB2 to these pathways. We also provide a molecular description of FA- or cancer-associated PALB2 mutations.
Collapse
|
20
|
Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples. Fam Cancer 2014; 13:583-9. [DOI: 10.1007/s10689-014-9730-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
21
|
Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe. Fam Cancer 2013; 13:137-42. [DOI: 10.1007/s10689-013-9684-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|